The startup B4-RNA presented promising data on the initial clinical performance of its technology at Harvard Medical School.
The presentation, delivered by founder and CSO Juan Pablo Tosar, included preliminary results from pilot studies in colorectal and lung cancer.
“We are very excited about our team’s achievements so far and the future of B4-RNA,” the startup said.
The company is developing technology that detects tumors at early stages, with the aim of improving cure rates and patients’ quality of life.
